Skip to main content
TISSUE REGENIX GROUP PLC logo

TISSUE REGENIX GROUP PLC — Investor Relations & Filings

Ticker · TRX ISIN · GB00BNTXR104 LEI · 213800PNOD5UHQUFJI36 IL Manufacturing
Open in API
Filings indexed 405 across all filing types
Latest filing 2022-12-07 Regulatory Filings
Country GB United Kingdom
Listing IL TRX

About TISSUE REGENIX GROUP PLC

https://www.tissueregenix.com/

Tissue Regenix Group PLC is a medical technology company specializing in regenerative medicine. The company develops and commercializes biological products designed to repair and regenerate human tissue. It employs proprietary decellularization platform technologies to process human and animal tissues, creating acellular scaffolds. When implanted, these scaffolds support the patient's own cells in repopulating and regenerating the damaged area. The company's portfolio serves three main clinical areas: biosurgery for complex wound care, orthopaedics for sports medicine and bone graft substitutes, and dental applications for tissue and bone repair. Key products include DermaPure®, OrthoPure® XT, and the Matrix® line of bone graft substitutes.

Recent filings

Filing Released Lang Actions
Product launch in dCELL® division
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 8347I' and contains standard regulatory boilerplate language at the end, including references to RNS, the London Stock Exchange, and the Financial Conduct Authority. The content announces a specific business event: the product launch of VNEW® Fascia Lata allograft by Tissue Regenix Group plc. This type of announcement, which is a material, non-financial operational update distributed via the RNS system, fits best under the general 'Regulatory Filings' category, as it is not a formal financial report (10-K, IR, ER), a management change (MANG), or a shareholder vote result (DVA). Given the source and nature (a timely, non-financial corporate update distributed through the official regulatory news service), RNS is the most appropriate classification.
2022-12-07 English
Distribution agreement - OrthoPure® XT in Germany
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 1322H' and concludes with a disclaimer stating, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This strongly indicates a regulatory announcement disseminated via the RNS system. The content itself is an announcement regarding a new distribution agreement for a product (OrthoPure® XT) in Germany. This type of material—a specific, non-periodic corporate update that doesn't fit into standard financial reports (10-K, IR, ER) or specific corporate actions (DIV, CAP, DIRS)—is best classified as a general regulatory filing or announcement. Since 'Regulatory Filings' (RNS) is the defined fallback for miscellaneous regulatory announcements, this is the most appropriate classification.
2022-11-22 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is explicitly labeled with 'RNS Number' and contains the standard footer information indicating it is provided by RNS, the news service of the London Stock Exchange, approved by the FCA. The content itself is a 'TR-1: Standard form for notification of major holdings,' which details changes in share ownership thresholds (crossing 10.0%). This type of mandatory disclosure regarding significant shareholdings falls under regulatory reporting. Since 'Major Shareholding Notification' (MRQ) is a specific category, and this document is a formal regulatory filing notification distributed via RNS, MRQ is the most precise classification for the content, even though it uses the RNS distribution channel.
2022-11-14 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is clearly identified as an 'RNS Number' filing from 'Tissue Regenix Group PLC' dated '07 November 2022'. The core content is a 'TR-1: Standard form for notification of major holdings'. This form details changes in voting rights held by a specific person/entity, crossing a notification threshold (from 8.4% to 9.8%). This type of filing, which reports changes in significant share ownership, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2022-11-07 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is identified by the 'RNS Number' header and contains specific details about a transaction involving a director/PDMR (Chief Executive Officer, Daniel Lee) purchasing company shares. This structure, including the transaction details table and the reference to 'Director/PDMR Shareholding', is characteristic of insider trading or director dealing notifications required by regulatory bodies (like the FCA via RNS). This directly matches the definition for Director's Dealing (DIRS). The document length is relatively short (4962 chars), but it is the primary filing itself, not an announcement of another report, so the RPA/RNS fallback is not necessary unless it didn't fit DIRS.
2022-09-29 English
Half-year Report
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Half-year Report' and 'Interim results for the six months to 30 June 2022'. It contains detailed financial statements, revenue breakdowns, operational highlights, and management commentary for the interim period. It is not a mere announcement of a report, but the report itself, containing substantive financial data. H1 2022
2022-09-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.